Julia N C Parlow

Dr. Julia N C Parlow

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Endocrinology
Verified
Journal Article
Closed access
PDF file
JPJulia N C Parlow
Julia N C Parlow
TPTristan J Philippe
Tristan J Philippe
MDMatthew Dordevic
Matthew Dordevic
LHLesley A Hill
Lesley A Hill
GHGeoffrey L Hammond
Geoffrey L Hammond
VVVictor Viau
Victor Viau
Produced by the liver, corticosteroid-binding globulin (CBG) regulates the plasma distribution and actions of glucocorticoids. A sex difference in pituitary growth hormone secretion patterns established during puberty in rats results in increased hepatic CBG production and two-fold higher plasma corticosterone levels in females. Glucocorticoids control hepatic development and metabolic activities, and we have therefore examined how disrupting the SerpinA6 gene encoding CBG influences plasma corticosterone dynamics, as well as liver gene expression in male and female rats before and after puberty. Comparisons of corticosterone plasma clearance and hepatic uptake in adult rats, with or without CBG, indicated that CBG limits corticosterone clearance by reducing its hepatic uptake. Hepatic transcriptomic profiling revealed minor sex differences (207 differentially expressed genes) and minimal effect of CBG deficiency in 30-day-old rats before puberty. While liver transcriptomes in 60-day-old males lacking CBG remained essentially unchanged, 2,710 genes were differentially expressed in wild-type female versus male livers at this age. Importantly, ∼10% of these genes lost their sexually dimorphic expression in adult females lacking CBG, including those related to cholesterol biosynthesis, inflammation, and lipid and amino acid catabolism. Another 203 genes were altered by the loss of CBG specifically in adult females, including those related to xenobiotic metabolism, circadian rhythm, and gluconeogenesis. Our findings reveal that CBG consolidates the sexual dimorphism of the rat liver initiated by sex differences in growth hormone secretion patterns and provide insight into how CBG deficiencies are linked to glucocorticoid-dependent diseases.

9 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LBLuke D. Boyle
Luke D. Boyle
AMAllende Miguelez-Crespo
Allende Miguelez-Crespo
MPMhairi Paul
Mhairi Paul
EVElisa Villalobos
Elisa Villalobos
JPJulia N C Parlow
Julia N C Parlow
MNMark Nixon
Mark Nixon
Corticosteroid binding globulin (CBG; SERPINA6) binds >85% of circulating glucocorticoids but its influence on their metabolic actions is unproven. Targeted proteolytic cleavage of CBG by neutrophil elastase (NE; ELANE) significantly reduces CBG binding affinity, potentially increasing ‘free’ glucocorticoid levels at sites of inflammation. NE is inhibited by alpha-1-antitrypsin (AAT; SERPINA1). Using complementary approaches in mice and humans to manipulate NE or AAT, we show high-fat diet (HFD) increases the NE:AAT ratio specifically in murine visceral adipose tissue, an effect only observed in males. Notably, HFD-fed male mice lacking NE have reduced glucocorticoid levels and action specifically in visceral adipose tissue, with improved glucose tolerance and insulin sensitivity, independent of systemic changes in free glucocorticoids. The protective effect of NE deficiency is lost when the adrenals are removed. Moreover, human asymptomatic heterozygous carriers of deleterious mutations in SERPINA1 resulting in lower AAT levels have increased adipose tissue glucocorticoid levels and action. However, in contrast to mice, humans present with systemic increases in free circulating glucocorticoid levels, an effect independent of HPA axis activation. These findings show that NE and AAT regulate local tissue glucocorticoid bioavailability in vivo, providing crucial evidence of a mechanism linking inflammation and metabolism.

2 December 2021 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
AFAnne Mette Frøbert
Anne Mette Frøbert
MBMalene Brohus
Malene Brohus
JPJulia N C Parlow
Julia N C Parlow
PRPhillip Round
Phillip Round
OFOle Fröbert
Ole Fröbert
MOMichael T. Overgaard
Michael T. Overgaard
Sex hormone‐binding globulin (SHBG) regulates the bioavailability of sex steroid hormones in the blood. Levels of SHBG increase markedly in brown bears (Ursus arctos) during hibernation, suggesting that a key regulatory role of this protein is to quench sex steroid bioavailability in hibernation physiology. To enable characterization of ursine SHBG and a cross species comparison, we established an insect cell‐based expression system for recombinant full‐length ursine and human SHBG. Compared with human SHBG, we observed markedly lower secretion levels of ursine SHBG, resulting in a 10‐fold difference in purified protein yield. Both human and ursine recombinant SHBG appeared as dimeric proteins in solution, with a single unfolding temperature of ~ 58 °C. The thermal stability of ursine and human SHBG increased 5.4 and 9.5 °C, respectively, in the presence of dihydrotestosterone (DHT), suggesting a difference in affinity. The dissociation constants for [3H]DHT were determined to 0.21 ± 0.04 nm for human and 1.32 ± 0.10 nm for ursine SHBG, confirming a lower affinity of ursine SHBG. A similarly reduced affinity, determined from competitive steroid binding, was observed for most steroids. Overall, we found that ursine SHBG had similar characteristics to human SHBG, specifically, being a homodimeric glycoprotein capable of binding steroids with high affinity. Therefore, ursine SHBG likely has similar biological functions to those known for human SHBG. The determined properties of ursine SHBG will contribute to elucidating its potential regulatory role in hibernation physiology.

12 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JPJulia N C Parlow
Julia N C Parlow
NSNicolas Salcedo-Porras
Nicolas Salcedo-Porras
FAFatma AlBulushi
Fatma AlBulushi
Stephen YipStephen Yip
Stephen Yip
EMEric McGinnis
Eric McGinnis
TSTara Spence
Tara Spence
Background/Objectives: Genomic alterations play a central role in diagnosis, prognostication, and therapeutic planning for hematolymphoid malignancies. At our tertiary care center, frontline genomic testing relies on optical genome mapping, karyotyping, and fluorescence in situ hybridization, with targeted next-generation sequencing (NGS) performed externally. To provide more comprehensive genomic profiling, we evaluated two large-panel NGS platforms and subsequently performed a clinical validation of the selected assay. Methods: The Illumina PanHeme DNA panel and the SOPHiA Genetics Community Myeloid Solution were compared using 24 bone marrow aspirate specimens with previously characterized alterations, including single nucleotide variants (SNVs), insertions/deletions (indels), and copy number variants (CNVs). The selected panel underwent full analytical validation using 60 specimens. Results: Both panels demonstrated excellent concordance for SNVs and indels, with comparable analytical performance and workflow. CNV calling with SOPHiA was notably strong. Platform selection was influenced by practical considerations, including panel content and cost, leading to a preference for further evaluation of the Illumina assay. Clinical validation of the Illumina PanHeme DNA panel, along with a complementary RNA Exome panel, was subsequently performed. Sequence variant detection showed 100% concordance with orthogonal testing, while CNV detection was variable, reflecting known limitations of targeted NGS. The RNA panel detected all expected fusion transcripts. Conclusions: These findings demonstrate robust analytical performance of both evaluated DNA panels. Clinical validation of the Illumina PanHeme DNA and RNA Exome assays supports their use for comprehensive molecular profiling of hematologic malignancies.

11 November 2026 in Canadian Journal of Medical Specialties
Verified
Journal Article
Closed access
JPJulia N C Parlow
Julia N C Parlow
TSTara Spence
Tara Spence
Optical genome mapping (OGM) provides high-resolution, genome-wide detection of structural and copy number variants in hematologic malignancies and has demonstrated increased diagnostic yield compared with conventional cytogenetics. Despite these advantages, karyotyping remains widely used in acute leukemia diagnostics. We examine the practical and analytical factors underlying continued reliance on conventional cytogenetic testing, with particular emphasis on turnaround time. At our institution, OGM has been implemented alongside karyotyping since 2023 and has been applied to more than 800 cases. While OGM improves detection of cryptic and complex genomic rearrangements, conventional karyotyping continues to deliver significantly faster preliminary and final results, which directly impact early clinical decision-making in acute leukemia. We describe our integrated diagnostic workflow and compare operational performance between modalities, highlighting trade-offs between genomic resolution and reporting speed. These findings support a complementary role for OGM while reinforcing the ongoing clinical necessity of rapid karyotyping in frontline acute leukemia diagnostics.

6 November 2026 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
FAFatma AlBulushi
Fatma AlBulushi
NSNicolas Salcedo-Porras
Nicolas Salcedo-Porras
JPJulia N C Parlow
Julia N C Parlow
CNChristine Nast
Christine Nast
ZHZeid Hamadeh
Zeid Hamadeh
EMEric McGinnis
Eric McGinnis
Accurate identification of KMT2A::MLLT10 fusions is essential for diagnostic classification and prognostication in acute myeloid leukemia and can guide therapeutic decision making. Detection of these fusions is diagnostically challenging due to the frequently cryptic and structurally complex nature of these events. In this study, we evaluated acute leukemia cases undergoing diagnostic workup with karyotyping and optical genome mapping (OGM), identified cases with KMT2A::MLLT10 fusions and retrospectively analyzed the structural events. During the period from September 2023 to April 2025, a total of five acute myeloid leukemia cases were identified which had a KMT2A::MLLT10 fusion. While OGM identified a KMT2A::MLLT10 rearrangement in all five cases, karyotype analysis showed no evidence of a rearrangement involving the KMT2A locus on 11q23 in four cases and fluorescence in situ hybridization (FISH) showed a normal signal pattern using a KMT2A break‐apart probe in interphase nuclei in three cases. Additionally, OGM revealed the complexity of the rearrangement events underlying fusion formation, generally including inversions ranging from less than 1 megabase to over 20 megabases in size along with variably sized deletions around the translocation breakpoints. Our study reveals that KMT2A::MLLT10 rearrangements are characterized by complex, multi‐break events with variable sizes of inversions of the translocated segments resulting in in‐frame fusions. These events were often difficult to detect by standard karyotype and interphase FISH, highlighting the value of high‐resolution methods like OGM in resolving these structurally complex events.